Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002632 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00002632 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 32 participants.
The verdict
NCT00002632, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic or recurrent salivary gland cancer.
Interventions
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1995-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002632
The ClinicalTrials.gov registry entry for NCT00002632 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel is the first listed.
NCT00002632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002632 about?
NCT00002632 is a clinical study titled "Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic or recurrent salivary gland cancer.
What is the current status of trial NCT00002632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 1995-05-30.
What interventions are being tested in trial NCT00002632?
The interventions under investigation include: paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00002632?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.